- Home
- DVAX vs DGII Comparison
DVAX vs DGII Comparison
Compare DVAX & DGII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- DGII
- Stock Information
- Founded
- DVAX 1996
- DGII 1985
- Country
- DVAX United States
- DGII United States
- Employees
- DVAX N/A
- DGII N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- DGII Computer peripheral equipment
- Sector
- DVAX Health Care
- DGII Technology
- Exchange
- DVAX Nasdaq
- DGII Nasdaq
- Market Cap
- DVAX 1.3B
- DGII 1.3B
- IPO Year
- DVAX 2004
- DGII N/A
- Fundamental
- Price
- DVAX $11.36
- DGII $33.54
- Analyst Decision
- DVAX Buy
- DGII Hold
- Analyst Count
- DVAX 4
- DGII 3
- Target Price
- DVAX $26.25
- DGII $35.67
- AVG Volume (30 Days)
- DVAX 1.6M
- DGII 149.6K
- Earning Date
- DVAX 08-05-2025
- DGII 08-06-2025
- Dividend Yield
- DVAX N/A
- DGII N/A
- EPS Growth
- DVAX N/A
- DGII 196.64
- EPS
- DVAX N/A
- DGII 1.13
- Revenue
- DVAX $294,620,000.00
- DGII $418,624,000.00
- Revenue This Year
- DVAX $21.18
- DGII $1.81
- Revenue Next Year
- DVAX $16.83
- DGII $4.34
- P/E Ratio
- DVAX N/A
- DGII $29.71
- Revenue Growth
- DVAX 24.76
- DGII N/A
- 52 Week Low
- DVAX $9.22
- DGII $20.17
- 52 Week High
- DVAX $14.63
- DGII $37.07
- Technical
- Relative Strength Index (RSI)
- DVAX 66.09
- DGII 48.55
- Support Level
- DVAX $10.38
- DGII $33.01
- Resistance Level
- DVAX $11.48
- DGII $33.72
- Average True Range (ATR)
- DVAX 0.30
- DGII 0.92
- MACD
- DVAX 0.08
- DGII -0.14
- Stochastic Oscillator
- DVAX 90.40
- DGII 35.24
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About DGII Digi International Inc.
Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.